Tillomed Laboratories

Company snapshot

Tillomed Laboratories maintains 51 tracked programs across No medical condition., No medical condition, Hormone receptor-positive early breast cancer in post-menopausal women, Dry Eye and Meibomian Gland Dysfunction, Inflammation and pain associated with ocular surgery, Parkinson´s disease, Alzheimer's disease, Diabetes, Chronic obstructive pulmonary disease, Hypercholesterolemia, Bioequivalence,

• 51 active pipeline program(s) linked via ClinicalTrials.gov.
• 51 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Tillomed Laboratories. Not investment advice.

• deal Jun 8, 2026

  Tillomed Laboratories update: pipeline, melphalan and next catalysts

• Peer + 0 momentum

  Esperion Therapeutics

  TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for Tillomed Laboratories.

1. Jun 8, 2026 Clinical update

   CFA-1034-2-23 — Phase 1

2. Jun 8, 2026 Clinical update

   CFA-1034-1-23 — Phase 1

3. Jun 8, 2026 Clinical update

   CFA-1028-2-23 — Phase 1

4. Jun 8, 2026 Clinical update

   THEA_HLF_1/21 — Approved

5. Jun 8, 2026 Clinical update

   CFA-1048-2-25 — Phase 1

View all clinical trial activity →

• What is Tillomed Laboratories?

  Laboratorios Tillomed Spain is a pharma organization headquartered in EU. Primary therapeutic focus areas include No medical condition., No medical condition, Hormone receptor-positive early breast cancer in post-menopausal women, Dry Eye and Meibomian Gland Dysfunction, Inflamma

• Is Tillomed Laboratories publicly traded?

  Tillomed Laboratories appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Tillomed Laboratories develop or market?

  We link 75 drug profile(s) where Tillomed Laboratories is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/laboratorios-tillomed-spain-s-l-u#company-drugs.

• What are the latest developments for Tillomed Laboratories?

  In the last 12 months our linked public records show 51 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Tillomed Laboratories focus on?

  Tillomed Laboratories focuses on No medical condition., No medical condition, Hormone receptor-positive early breast cancer in post-menopausal women based on our analysis of their pipeline programs and drug development activities.